BNT162b2 booster vaccination elicits cross-reactive immunity against SARS-CoV-2 variants B.1.1.529 and B.1.617.2 in convalescents of all ages
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Frontiers in Immunology ; 13 (2022). - Art.-Nr. 920210. - eISSN 1664-3224
- Keyword
-
COVID-19
mRNA-Impfstoff
Immunreaktion
- Event
-
Veröffentlichung
- (where)
-
Ulm
- (who)
-
Universität Ulm
- (when)
-
2022
- Creator
-
Jahrsdörfer, Bernd
Proffen, Matthias
Scholz, Judith
Hägele, Janina
Ludwig, Carolin
Vieweg, Christiane
Grempels, Aline
Fabricius, Dorit
Lotfi, Ramin
Körper, Sixten
Adler, Guido
Schrezenmeier, Hubert
- DOI
-
10.18725/OPARU-44643
- URN
-
urn:nbn:de:bsz:289-oparu-44719-1
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:42 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jahrsdörfer, Bernd
- Proffen, Matthias
- Scholz, Judith
- Hägele, Janina
- Ludwig, Carolin
- Vieweg, Christiane
- Grempels, Aline
- Fabricius, Dorit
- Lotfi, Ramin
- Körper, Sixten
- Adler, Guido
- Schrezenmeier, Hubert
- Universität Ulm
Time of origin
- 2022
Other Objects (12)
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Vaccination against SARS-CoV-2: a human enhancement story
IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Vaccination against SARS-CoV-2: a human enhancement story
IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein
SARS-CoV-2 specific cellular and humoral immunity after bivalent BA.4/5 COVID-19 vaccination in previously infected and non-infected individuals
Predictors of impaired SARS-CoV-2 immunity in healthcare workers after vaccination with BNT162b2
SARS-CoV-2 immunity through vaccination and infection in healthy individuals and haemodialysis patients
Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients
Spike-specific T cell immunity following vaccination against the human coronaviruses SARS-CoV-2 and MERS-CoV
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects
BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Vaccination against SARS-CoV-2: a human enhancement story
IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination
Long-term immune protection against SARS-CoV-2 escape variants upon a single vaccination with murine cytomegalovirus expressing the spike protein